NCT06104930 Plasma Extracellular Vesicles in Meningioma Patients
| NCT ID | NCT06104930 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Heidelberg |
| Condition | Meningioma |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2027-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2023-11-01 with a primary completion date of 2027-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
While surgical resection remains the primary treatment approach for symptomatic or growing meningiomas, radiotherapy represents an auspicious alternative in patients with meningiomas not safely amenable to surgery. Biopsies are often omitted in light of potential postoperative neurological deficits, resulting in a lack of histological grading and (molecular) risk stratification. In this prospective explorative biomarker study, extracellular vesicles in the bloodstream will be investigated in patients with macroscopic meningiomas to identify a biomarker for molecular risk stratification and disease monitoring.
Eligibility Criteria
Inclusion Criteria: * confirmed meningioma (histologically or MRI/DOTATOC-PET CT) * macroscopic tumor in MRI (either as definitive RT, or following subtotal resection or relapse) * indication for radiotherapy * completed wound healing after surgical intervention) * Alter ≥ 18 Jahre * Karnofsky Performance Score ≥ 60% * written informed consent * ability of subject to understand character and individual consequences of the trial * adequate contraception for women of childbearing potential Exclusion Criteria: * previous or known tumor diseases \< 5 years ago * previous (cerebral) radiotherapy * simultaneous chemo/immunotherapy * evidence that the patient cannot adhere to the study protocol (e.g., non-compliance) * the refusal of patients to participate in the study * participation in another clinical study or observation period in a competing trial
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06104930 clinical trial?
This trial is open to participants of all sexes, studying Meningioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06104930 currently recruiting?
Yes, NCT06104930 is actively recruiting participants. Contact the research team at maximilian.deng@med.uni-heidelberg.de for enrollment information.
Where is the NCT06104930 trial being conducted?
This trial is being conducted at Heidelberg, Germany.
Who is sponsoring the NCT06104930 clinical trial?
NCT06104930 is sponsored by University Hospital Heidelberg. The trial plans to enroll 60 participants.